A 48-week Phase 2 trial reported in The Lancet in 2025 showed mean weight reduction ranging from approximately 9% at the lowest dose to 20% at the highest dose, compared with 0.4% on placebo
Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone anatgonist
-20C, 1 month (sealed storage, away from moisture and light) Publications (1) Journal Impact Factor Most Recent J Appl Toxicol Copper induces oxidative stress and apoptosis of hippocampal neuron via pCREB/BDNF/ and Nrf2/HO-1/NQO1 pathway
Protect: Sun exposure can trigger rosacea, use sunscreen with SPF 30+ daily to protect your skin
KLOW Peptide Therapy in New York & NYC | BPC-157, TB-500, KPV & GHK-Cu KLOW Peptide Therapy for Recovery, Wellness and Healthy Aging Support KLOW is a multi-peptide wellness blend that combines BPC-157 , TB-500, KPV and GHK-Cu in one physician-guided program